Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits
Ono Pharmaceutical suffered a 4.7% sales decline for its flagship PD-1 inhibitor Opdivo (nivolumab) in April-December as its label expansions failed to counter its 37.5% price cut in November 2018 and ever-intensifying competition on the market. Despite the fall, the…
To read the full story
Related Article
- Ono’s FY2019 Sales Up 1.3% on Keytruda-Tied Royalties
May 13, 2020
- Ono Checks In 3.2% Revenue Growth on Opdivo, Forxiga in 1st Half
November 1, 2019
- Ono’s Drug Sales Skid in Q1, but Opdivo Royalties Underpin Earnings
August 2, 2019
BUSINESS
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…